Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
27 hedge funds and large institutions have $17.2M invested in Aevi Genomic Medicine Inc in 2014 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 4 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
11% more capital invested
Capital invested by funds: $15.4M → $17.2M (+$1.75M)
4% less funds holding
Funds holding: 28 → 27 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$135K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$125K |
| 3 |
WA
WFG Advisors
Dallas,
Texas
|
+$38.1K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$21.2K |
| 5 |
VanEck Associates
New York
|
+$16.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$289K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$149K |
| 3 |
PA
Perceptive Advisors
New York
|
-$43.7K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$19.4K |
| 5 |
KCPG
Kavar Capital Partners Group
Leawood,
Kansas
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| $5K | +$4.95K | +700 | New |
|
27
BNP Paribas Financial Markets
Paris,
France
| $2.39K | – | – | – |
|
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$149K | -21,075 | Closed |
|
|
KCPG
29
Kavar Capital Partners Group
Leawood,
Kansas
| – | -$13K | -2,000 | Closed |
|
|
TDC
30
Thompson Davis & Co
Richmond,
Virginia
| – | -$5K | -750 | Closed |
|
GNMX Hedge Fund Activity: Q2 2014 in Review
27 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q2 2014, worth a combined $17.2M — up 11% from $15.4M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GNMX and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 8 added.
The largest buyer was BlackRock Institutional Trust, adding an estimated $135K. The largest seller was Morgan Stanley, cutting an estimated $289K.
- 27 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q2 2014, down from 28 in Q1 2014.
- Funds reported $17.2M of Aevi Genomic Medicine Inc stock for Q2 2014, up 11% quarter-over-quarter.
- 3 funds opened new Aevi Genomic Medicine Inc positions in Q2 2014 and 4 closed out, a net change of -1 holder.
- The largest Aevi Genomic Medicine Inc buyer in Q2 2014 was BlackRock Institutional Trust, an estimated $135K added.
- The largest Aevi Genomic Medicine Inc seller in Q2 2014 was Morgan Stanley, an estimated $289K sold.
Based on aggregated 13F filings for Q2 2014.